Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03526926

A Post-Marketing Observational Study of VYXEOS™

Therapy-Related Acute Myeloid Leukemia Clinical Trial

Official title:
A Post-Marketing Observational Study of VYXEOS™ to Assess the Incidence of Infusion-Related Reactions in Adult Patients

Clinical Trial Summary

The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03526926
Study type Observational
Source Jazz Pharmaceuticals
Contact
Status Completed
Phase
Start date October 23, 2018
Completion date June 12, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04062266 - AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission Phase 2
Terminated NCT03272633 - Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Early Phase 1
Completed NCT04518345 - TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia Early Phase 1
Completed NCT01420926 - Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia Phase 2
Recruiting NCT04128501 - Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting Phase 2
Active, not recruiting NCT01619761 - NK Cells in Cord Blood Transplantation Phase 1
Completed NCT01130506 - Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Active, not recruiting NCT02658487 - Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia Phase 2
Completed NCT01823198 - Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Phase 1/Phase 2
Withdrawn NCT03602898 - Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation Phase 2
Active, not recruiting NCT03226418 - Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia Phase 2
Recruiting NCT04269213 - CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old Phase 2
Completed NCT02323607 - Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations Phase 1
Recruiting NCT06143839 - VYxeoS Liposomal Italian Observational Study iN the Real Practice
Terminated NCT01640301 - Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT01760655 - Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Phase 2
Completed NCT01238211 - Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Phase 2
Active, not recruiting NCT03009240 - Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia Phase 1
Terminated NCT02381548 - Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia Phase 1
Completed NCT02397720 - Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia Phase 2